180 Chapter 7 45. Young, H. S., Ceholski, D. K. & Trieber, C. A. Deception in simplicity: hereditary phospholamban mutations in dilated cardiomyopathy. Biochem. Cell Biol. 93, (2015). 46. Karakikes, I. et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat. Commun. 6, 6955 (2015). 47. López-Ayala, J. M. et al. Phospholamban p.arg14del mutation in a Spanish family with arrhythmogenic cardiomyopathy: evidence for a European founder mutation. Rev. Esp. Cardiol. 68, (2015). 48. Fish, M. et al. Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci. Rep. 6, 22235 (2016). 49. Milano, A. et al. Sudden Cardiac Arrest and Rare Genetic Variants in the Community. Circ. Cardiovasc. Genet. 9, 147–153 (2016). 50. Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542–550 (2016). 51. Stillitano, F. et al. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur. Heart J. 37, 3282–3284 (2016). 52. van Opbergen, C. J. M., Delmar, M. & van Veen, T. A. B. Potential new mechanisms of pro-arrhythmia in arrhythmogenic cardiomyopathy: focus on calcium sensitive pathways. Netherlands Heart Journal vol. 25 157–169 Preprint at https://doi.org/10.1007/s12471-017-0946-7 (2017). 53. Sepehrkhouy, S. et al. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm 14, 1024–1032 (2017). 54. Te Rijdt, W. P. et al. Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovasc. Pathol. 30, 23–26 (2017). 55. Nannenberg, E. A. et al. Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. Circ Genom Precis Med 11, e001797 (2018). 56. Wu, H. et al. Engineering CRISPR/Cpf1 with tRNA promotes genome editing capability in mammalian systems. Cell. Mol. Life Sci. 75, 3593–3607 (2018). 57. Hof, I. E. et al. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth. Heart J. 27, 64–69 (2019). 58. Te Rijdt, W. P. et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur. Heart J. Cardiovasc. Imaging 20, 92–100 (2019). 59. Cheung, C. C. et al. Phospholamban cardiomyopathy: a Canadian perspective on a unique population. Neth. Heart J. 27, 208–213 (2019). 60. Doevendans, P. A., Glijnis, P. C. & Kranias, E. G. Leducq Transatlantic Network of Excellence to Cure Phospholamban-Induced Cardiomyopathy (CURE-PLaN). Circ. Res. 125, 720–724 (2019). 61. Stroik, D. R. et al. Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs. J. Mol. Cell. Cardiol. 138, 59–65 (2020). 62. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, 9819 (2020). 63. Bleijendaal, H. et al. Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram? Heart Rhythm 18, 79–87 (2021). 64. Jiang, X. et al. The phenotypic characteristic observed by cardiac magnetic resonance in a PLN-R14del family. Sci. Rep. 10, 1–6 (2020). 65. Menzel, J. et al. 14-3-3 binding creates a memory of kinase action by stabilizing the modified state of phospholamban. Sci. Signal. 13, (2020). 66. Pei, J. et al. Transcriptional regulation profiling reveals disrupted lipid metabolism in failing hearts with a pathogenic phospholamban mutation. bioRxiv 2020.11.30.402792 (2020) doi:10.1101/2020.11.30.402792. 67. Taha, K. et al. Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of Symptoms. JACC Cardiovasc. Imaging 14, 885–896 (2021).
RkJQdWJsaXNoZXIy MTk4NDMw